KR20190134718A - 전립선암을 위한 병용 요법 - Google Patents

전립선암을 위한 병용 요법 Download PDF

Info

Publication number
KR20190134718A
KR20190134718A KR1020197032257A KR20197032257A KR20190134718A KR 20190134718 A KR20190134718 A KR 20190134718A KR 1020197032257 A KR1020197032257 A KR 1020197032257A KR 20197032257 A KR20197032257 A KR 20197032257A KR 20190134718 A KR20190134718 A KR 20190134718A
Authority
KR
South Korea
Prior art keywords
patient
prednisone
abiraterone acetate
administering
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197032257A
Other languages
English (en)
Korean (ko)
Inventor
마가렛 케이. 유
린다 앤 스나이더
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190134718(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Priority to KR1020267009381A priority Critical patent/KR20260048358A/ko
Publication of KR20190134718A publication Critical patent/KR20190134718A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020197032257A 2017-04-13 2018-04-09 전립선암을 위한 병용 요법 Ceased KR20190134718A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267009381A KR20260048358A (ko) 2017-04-13 2018-04-09 전립선암을 위한 병용 요법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
US62/485,164 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267009381A Division KR20260048358A (ko) 2017-04-13 2018-04-09 전립선암을 위한 병용 요법

Publications (1)

Publication Number Publication Date
KR20190134718A true KR20190134718A (ko) 2019-12-04

Family

ID=62067858

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197032257A Ceased KR20190134718A (ko) 2017-04-13 2018-04-09 전립선암을 위한 병용 요법
KR1020267009381A Pending KR20260048358A (ko) 2017-04-13 2018-04-09 전립선암을 위한 병용 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267009381A Pending KR20260048358A (ko) 2017-04-13 2018-04-09 전립선암을 위한 병용 요법

Country Status (33)

Country Link
US (4) US20180296574A1 (enExample)
EP (3) EP4176879A1 (enExample)
JP (3) JP7141408B2 (enExample)
KR (2) KR20190134718A (enExample)
CN (2) CN119235874A (enExample)
AU (2) AU2018251594A1 (enExample)
CA (1) CA3059562A1 (enExample)
CL (1) CL2019002871A1 (enExample)
CO (1) CO2019011591A2 (enExample)
CR (1) CR20190467A (enExample)
DK (1) DK3609497T3 (enExample)
DO (1) DOP2019000264A (enExample)
EA (1) EA201992430A1 (enExample)
ES (1) ES2931052T3 (enExample)
HR (1) HRP20221327T1 (enExample)
HU (1) HUE060460T2 (enExample)
IL (2) IL269879B2 (enExample)
JO (2) JOP20190244B1 (enExample)
LT (1) LT3609497T (enExample)
MA (1) MA48728B1 (enExample)
MD (1) MD3609497T2 (enExample)
MX (2) MX2019012296A (enExample)
MY (1) MY209010A (enExample)
NI (1) NI201900105A (enExample)
PE (1) PE20200444A1 (enExample)
PH (1) PH12019502317A1 (enExample)
PL (1) PL3609497T3 (enExample)
PT (1) PT3609497T (enExample)
RS (1) RS63832B1 (enExample)
SG (1) SG11201909552VA (enExample)
SM (1) SMT202200467T1 (enExample)
UA (1) UA129514C2 (enExample)
WO (1) WO2018191141A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
AU2021269115A1 (en) * 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
KR20230159510A (ko) * 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
TWI828471B (zh) 2021-12-15 2024-01-01 大陸商湖南慧澤生物醫藥科技有限公司 醋酸阿比特龍的自微乳組合物和應用
CN118973555A (zh) * 2022-04-07 2024-11-15 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PL2061561T3 (pl) * 2006-08-25 2013-12-31 Janssen Oncology Inc Kompozycje do leczenia raka
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
CL2019002871A1 (es) 2019-12-27
ES2931052T3 (es) 2022-12-23
SG11201909552VA (en) 2019-11-28
MY209010A (en) 2025-06-16
US20240245710A1 (en) 2024-07-25
LT3609497T (lt) 2022-12-12
DOP2019000264A (es) 2020-07-15
EA201992430A1 (ru) 2020-02-28
PE20200444A1 (es) 2020-02-28
EP4176879A1 (en) 2023-05-10
JP2022141881A (ja) 2022-09-29
MA48728B1 (fr) 2022-10-31
JP2024023344A (ja) 2024-02-21
EP3609497A1 (en) 2020-02-19
WO2018191141A1 (en) 2018-10-18
CA3059562A1 (en) 2018-10-18
BR112019021466A2 (pt) 2020-05-12
PT3609497T (pt) 2023-01-23
EP3609497B1 (en) 2022-10-12
US20180296574A1 (en) 2018-10-18
IL269879A (enExample) 2019-11-28
MX2019012296A (es) 2019-11-28
IL269879B2 (en) 2025-10-01
RS63832B1 (sr) 2023-01-31
MD3609497T2 (ro) 2023-03-31
HRP20221327T1 (hr) 2023-03-17
US20240398837A1 (en) 2024-12-05
JP2020516646A (ja) 2020-06-11
JP7141408B2 (ja) 2022-09-22
AU2024202346A1 (en) 2024-05-02
NI201900105A (es) 2020-03-11
MA48728A (fr) 2020-04-08
CN119235874A (zh) 2025-01-03
CN110753545A (zh) 2020-02-04
KR20260048358A (ko) 2026-04-09
JP7407880B2 (ja) 2024-01-04
SMT202200467T1 (it) 2023-01-13
MX2023009569A (es) 2023-08-22
JOP20230159A1 (ar) 2023-07-13
AU2018251594A1 (en) 2019-10-24
JOP20190244A1 (ar) 2019-10-13
AU2024202346B2 (en) 2026-01-22
CO2019011591A2 (es) 2020-02-28
US20220175801A1 (en) 2022-06-09
JOP20190244B1 (ar) 2024-04-18
IL269879B1 (en) 2025-06-01
PL3609497T3 (pl) 2023-01-23
EP4176878A1 (en) 2023-05-10
UA129514C2 (uk) 2025-05-21
PH12019502317A1 (en) 2020-07-06
HUE060460T2 (hu) 2023-03-28
IL320452A (en) 2025-06-01
CR20190467A (es) 2020-03-09
DK3609497T3 (da) 2022-10-31

Similar Documents

Publication Publication Date Title
JP7407880B2 (ja) 前立腺癌の併用療法
Hoy Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer
JP2016515586A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
KR20210110794A (ko) B-Raf 억제제와 제2 억제제를 포함하는 조합 요법
JP2024510612A (ja) ソトラシブ投与レジメン
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
JP2022518235A (ja) 進行期固形腫瘍がんの治療用ｒｎａ
HK40092155A (en) Combination therapy for prostate cancer
EA052155B1 (ru) Комбинированная терапия рака предстательной железы
EA044835B1 (ru) Комбинированная терапия рака предстательной железы
BR122022022077B1 (pt) Combinação e composição compreendendo niraparibe, acetato de abiraterona, e prednisona, seu uso para tratar câncer de próstata e kit
BR112019021466B1 (pt) Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos
JP2008526773A (ja) ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療
Vicente-Baz et al. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: clinical characteristics and genotyping methods in a Spanish cohort
EP4665725A2 (en) Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations
CN116981462A (zh) 索托拉西布给药方案
Kollepara et al. Integrating Emerging Science into Clinical Practice: Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer
Kübier et al. 7046 POSTER Final Analysis of a Phase l/lla Study With CV9103, an Intradermally Administered Prostate Cancer Immunotherapy Based on Self Adjuvanted mRNA

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE)